SCHEMBL20148709

SCHEMBL20148709

CC(C)N1CC2CC(C1)N2C(=O)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA4 P43681 1/20 0.46
ALDH1A1 P00352 2/20 0.41
PDE10A Q9Y233 1/20 0.41
RBP4 P02753 1/20 0.41
RIPK1 Q13546 1/20 0.40
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
SNRNP200 O75643 3/20 0.39
LMNA P02545 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23555020 0.90 L3MBTL1 (0.46) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20069577 0.85 L3MBTL1 (0.51) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20148714 0.82 PDE10A (0.43) ALDH1A1PDE10ALMNASMN1; SMN2RET
SCHEMBL20154521 0.81 L3MBTL1 (0.48) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL26250601 0.80 L3MBTL1 (0.53) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL25395834 0.80 L3MBTL1 (0.53) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20148708 0.80 PDE10A (0.42) PDE10ARETGRM5
SCHEMBL20148707 0.80 TDP1 (0.44) L3MBTL1PDE10ARET
SCHEMBL20148704 0.79 PDE10A (0.44) PDE10ASMN1; SMN2RETGRM5
SCHEMBL20148712 0.79 P2RX7 (0.40) ALDH1A1KDM4ERET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-03-23 US disclosed
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-10953005-B1 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF L3MBTL1 1445/4885CHRNB2 2276/4885CHRNB4 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.